
Personalized mRNA Vaccines Tested in Melanoma Patients
The story in brief
A study tested 1,100 high-risk melanoma patients who had undergone complete surgical removal of visible disease. They received personalized mRNA vaccines, designed with AI and each patient’s tumour genetic profile, combined with pembrolizumab. The vaccines aim to train the immune system to target specific mutations. This builds on checkpoint inhibitors’ success in melanoma, which expanded to other cancers, reshaping treatment paradigms.